Thank you - I think for reading the updated feedback today. This is taking that into account but I have to say that it is very hard to see both the U and the I. Its like one of those cool pictures that you see different things if you stare at it long enough. First I saw what looked like a blue test tube and a green test tube or J next to the N. Then I realized it was a U turned but there really is no I?
I think you read updates to the brief today based on this new entry - but I will re-iterate to see notes from today. Interesting but a little off with focus we asked to be on U and I and simple enough to see the word when looking at it. See updated brief under comments.
I would say that feedback was on less focus on hexagon, more focus on the U and the I or even tying them together somehow, making them stand out as a combo....We decided to use GENUINE or another name RUBICON for our first trial and UNITY for a different trial (combines Ublituximab and TGR-1202 for U and T).
That said however - for GENUINE - remember the importance of the U and the I being key. We like the word and what it stands for - we see the chance to highlight "our" drug with "U" (an antibody) and the idea of a combo with the I drug (a BCR receptor inhibitor of BTK - less important). Maybe even tying them together somehow. Please see the updated comments at brief about that and also about focusing on the science behind the drugs possibly (shapes of the pathways inhibited - search antiCD20 antibody or BCR receptor) in the logo or any design element. It is valuable feedback from our CEO, COO and team to make a decision with me. THANKS AGAIN!